Spectrum Pharmaceuticals completes enrollment in Phase III bladder cancer trial
Spectrum Pharmaceuticals has reported that one of the two Phase III pivotal clinical trials of apaziquone has achieved enrollment target, having enrolled approximately 800 patients. The second Phase III clinical trial of apaziquone is expected to complete enrollment by the end of 2009. The apaziquone registration plan calls for two double blind, randomized Phase III clinical studies, each with 562 patients with Ta G1 or G2 low risk non-invasive bladder cancer.
- EOquin granted fast-track designation for bladder cancer
- Prevention Of Organ Rejection In Stable Kidney Transplant Patients – LCP-Tacro™ Moves Into Clinical Phase 3
- KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism
- Urocidin receives fast track status from FDA
